Triple Drug Regimen Is Effective in Drug-resistant Hepatitis C Treatment

16 აგვისტო 2017

American researchers from the Infectious Diseases Denver Health, Medical Center, University of Colorado have found that three drugs of  grazoprevir, ruzasvir, and uprifosbuvir combined shown great efficiency in drug-resistant Hepatitis C treatment and published the results of the trials in Hepatology online journal.

"Effective treatment options for people who have failed the current generation of all-oral DAA regimens will require a combination of drugs of sufficient potency to overcome multiple negative predictors, while simultaneously presenting a high barrier to resistance to overcome baseline RASs (potentially multi-class) and prevent emergence of new RASs. The lack of virologic failures is impressive, particularly in the very difficult to treat C-SURGE study population. However, further studies are needed to determine if shorter durations and the omission of RBV from the treatment regimen maintain this high cure rate." - said said  David L Wyles, header of the trial,  MD, Chief of Infectious Diseases Denver Health, Medical Center, University of Colorado.